Author reply
We appreciate the opportunity to respond to the letter by Coupland and Damato regarding our 2012 article. Contrary to their claim, the gene expression profile (GEP) prognostic test for uveal melanoma has undergone much greater validation than any other competing technology, and it is the only one that has been validated in a prospective multicenter study. It meets the highest National Comprehensive Cancer Network “level I” evidence for cancer biomarkers, whereas the Liverpool group has achieved only a level III with their multiplex ligation-dependent probe amplification (MLPA) technique.